Immutrin raises £65 million in Series A funding to advance amyloidosis therapy
We’re delighted that Milner Institute Bio-incubator company Immutrin has announced the successful close of a £65 million ($87 million) Series A financing round to develop a next-generation antibody therapy for ATTR amyloidosis. This funding will enable Immutrin to...
Milner Institute to showcase collaboration and innovation at BioTrinity 2026
We’re delighted to announce that the Milner Therapeutics Institute will play an active role at BioTrinity 2026 next month, with both a dedicated showcase session and participation in a key panel discussion focused on collaboration in life sciences. BioTrinity...
Flagship–Cambridge partnership marks one year of therapeutic innovation and collaboration
In 2025, the Milner Therapeutics Institute, together with Cambridge University Health Partners, announced a collaboration with Flagship Pioneering – a scientific innovation engine for transformative platforms and products in human health, sustainability, and beyond....
Milner Institute hosts Cambridge–Oxford BioVenture Showcase, spotlighting high-potential biotech startups
On 22 January, we were delighted to host the Cambridge–Oxford BioVenture Showcase, bringing together innovators, early‑stage founders, researchers, investors, and industry partners from the Cambridge-Oxford corridor. The showcase created a dynamic forum for...